Kymera Therapeutics (KYMR) Revenue (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Revenue of $34.4 million for Q1 2026, up 55.5% year-over-year from $22.1 million in Q1 2025, and up 1097.39% quarter-over-quarter from $2.9 million in Q4 2025.
Kymera Therapeutics (KYMR) Revenue (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Revenue for 8 consecutive years, with $34.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 55.5% year-over-year to $34.4 million; the TTM figure through Mar 2026 stood at $51.5 million (down 12.58% YoY), while the FY2025 annual figure was $39.2 million, down 16.7% from the prior year.
- Revenue improved to $34.4 million in Q1 2026 per KYMR's latest filing, from $2.9 million in the prior quarter.
- Across five years, Revenue topped out at $47.9 million in Q4 2023 and bottomed at $2.8 million in Q3 2025.
- Historically, Revenue has averaged $14.5 million across 5 years, with a median of $10.3 million in 2024.
- Annual changes were most pronounced in 2023 — Revenue soared 196.7% — and 2024, when it sank 84.56%.
- Kymera Therapeutics' Revenue stood at $16.1 million in 2022, then soared by 196.7% to $47.9 million in 2023, then tumbled by 84.56% to $7.4 million in 2024, then slumped by 61.18% to $2.9 million in 2025, then soared by 1097.39% to $34.4 million in 2026.
- Business Quant data shows KYMR's Revenue at $34.4 million in Q1 2026, $2.9 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 65.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.00 Mn |
| Mar 31, 2026 | 34.37 Mn |
| Dec 31, 2025 | 2.87 Mn |
| Sep 30, 2025 | 2.76 Mn |
| Jun 30, 2025 | 11.48 Mn |
| Mar 31, 2025 | 22.10 Mn |
| Dec 31, 2024 | 7.39 Mn |
| Sep 30, 2024 | 3.74 Mn |
| Jun 30, 2024 | 25.65 Mn |
| Mar 31, 2024 | 10.29 Mn |
| Dec 31, 2023 | 47.89 Mn |
| Sep 30, 2023 | 4.73 Mn |
| Jun 30, 2023 | 16.51 Mn |
| Mar 31, 2023 | 9.47 Mn |
| Dec 31, 2022 | 16.14 Mn |
| Sep 30, 2022 | 9.55 Mn |
| Jun 30, 2022 | 11.51 Mn |
| Mar 31, 2022 | 9.62 Mn |
| Dec 31, 2021 | 15.28 Mn |
| Sep 30, 2021 | 20.34 Mn |